Clinical trials: Influenza Virus Infection
Influenza
Human Infection Study of H3N2 Influenza in Healthy Adults
This study will examine how the immune system responds to a flu virus (H3N2) during and after infection in health adults aged between 18 and 50 while in an inpatient facility.
- Trial name
- FluCHIM (NCT06972810)
- Testing
- A/Texas/71/2017, clade 3C3a H3N2 influenza virus
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Influenza
Vitamin A and Maternal-infant Flu Vaccine Response
Influenza viral infection can cause serious illness among young infants 0-6 months of age. However, inactivated influenza vaccine is not recommended for this age group but pregnant women can be vaccinated during 2nd - 3rd…
- Trial name
- NCT00817661
- Testing
- Vitamin A
- Where
- Bangladesh
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Influenza
Influenza Vaccine in Pediatric Transplant Subjects
The purpose of this study is to evaluate how well children responds to the recommended trivalent subviron influenza vaccine (flu shot).
- Trial name
- NCT00133510
- Testing
- Trivalent Subviron Influenza vaccine (Fluzone)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Drug Use Investigation for Arepanrix® (H1N1)
This post-marketing surveillance study is designed to collect safety information such as post-vaccination adverse events and adverse reactions from recipients of Arepanrix® (H1N1) Intramuscular Injection.
- Trial name
- NCT02069496
- Testing
- Arepanrix®
- Volunteers
- 3,405 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Influenza
Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients
To estimate the incidence of H1N1v influenza-like illness and to study the risk factors for serious influenza forms during pandemic period in French HIV infected patients.
- Trial name
- ANRS 2H (NCT01039220)
- Testing
- naso-pharyngeal swab
- Where
- France
- Volunteers
- 1,266 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Mucosal Immune Response to Influenza Vaccination
How Healthy Adults Respond to the Nasal Flu Vaccine
This study is looking at how the immune system in the nose responds after receiving the FluMist nasal flu vaccine in healthy adults. FluMist is an FDA-approved influenza vaccine that is given as a nasal spray.
- Trial name
- MOSAIC (NCT07726862)
- Testing
- FluMist (Live Attenuated Influenza Vaccine)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Influenza
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years
The aim of the trial is to evaluate immunogenicity and safety of the quadrivalent influenza vaccine (QIV) and the trivalent influenza vaccine (TIV) (split-virion inactivated) Northern Hemisphere (NH) 2015 2016 seasonal…
- Trial name
- NCT02550197
- Testing
- Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016, Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
- Where
- 5 sites in South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines
This trial is designed to evaluate safety, tolerability and immunogenicity of a bedside mixing formulation of adjuvanted influenza vaccines.
- Trial name
- NCT00735020
- Testing
- Adjuvanted Influenza Vaccine, Influenza Vaccine
- Where
- Switzerland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines
The purpose of this study is to compare two licensed influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and the safety/ any symptoms that may occur for up to six months after vaccination.
- Trial name
- NCT00197288
- Testing
- Influenza
- Where
- 15 sites in United States
- Volunteers
- 1,847 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
- Trial name
- NCT01990846
- Testing
- Flufirvitide 3
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
Influenza, Flu
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
The aim of the study was to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone Quadrivalent vaccine in children 6 months to < 9 years of age, and in adults 18 to < 65 years of age, and to describe the…
- Trial name
- NCT03308825
- Testing
- Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza and Acute Respiratory Viral Infections
Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children
The purpose of this study is: To obtain additional data on therapeutic efficacy of Anaferon for children in the treatment of influenza and acute respiratory viral infections in children
- Trial name
- NCT02072174
- Testing
- Anaferon for Children
- Where
- 27 sites in Belarus, Russia and 1 more
- Volunteers
- 569 people
- Sponsor
- Materia Medica Holding
Influenza
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
The present study is a first-in-man clinical trial evaluating OVX836, a recombinant broad spectrum vaccine for Influenza. This clinical trial will evaluate the safety and the immune response of increasing doses of OVX836 after…
- Trial name
- NCT03594890
- Testing
- OVX836 (Intramuscular), OVX836 (Intranasal)
- Where
- Belgium
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza
Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities
While the COVID-19 pandemic has highlighted health disparities, Black children have unduly suffered and died from seasonal influenza for decades.
- Trial name
- NCT06274359
- Testing
- Digital storytelling
- Where
- 2 sites in United States
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Inflammatory Bowel Disease (IBD)
Efficacy Safety Study of Flu Vaccine in Immunodepression Patients
The primary purpose of the study is to compare the efficacy and safety of influenza vaccine in patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapy with patients not receiving immunosuppressants .
- Trial name
- MICIVAX (NCT01022749)
- Testing
- Vaccine, Vaccine anti-H1N1
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Syncytial Virus, Human Metapneumovirus
Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses
Collection of nasal secretions from infants and toddlers for viral testing is usually done using the nasal washing technique described by Hall in 1975. This is cumbersome.
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus, Influenza, Bronchiolitis
- Trial name
- NCT00613184
- Testing
- Nylon Flocked swab (Nasal secretion sampling)
- Volunteers
- 150 people
- Sponsor
- Kern Medical Center
Influenza
Immunogenicity of Standard-Dose Versus High-Dose Influenza Vaccines in Older Adults in Singapore
The goal of this clinical trial is to learn if the high-dose influenza vaccine can improve year-round protection in older adults aged 60 years and above.
- Trial name
- SingVax-01 (NCT07883421)
- Testing
- High-dose influenza vaccine, Standard-dose influenza vaccine
- Where
- Singapore
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Severe Influenza
Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms
This is a multicenter, randomized, open Label, add-on study.
- Trial name
- NCT03947411
- Testing
- Oseltamivir Phosphate, Xiyanping injection+Oseltamivir Phosphate
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Influenza A Virus Infection, Influenza A
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
The present clinical phase I study designed to examine the safety, reactogenicity and immunogenicity of the medicinal product - Vaccine vector against influenza A - in healthy volunteers after a single dose in the three groups…
- Conditions
- Influenza A Virus Infection, Influenza A, Influenza Epidemic, Influenza H5N1
- Trial name
- NCT03651544
- Testing
- GamFluVac
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults
To perform a variety of assays on blood, serum, nasal wash samples and cells obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by…
- Trial name
- NCT00192192
- Testing
- CAIV-T
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.